

Innovating Mental Health and Wellness

Next Level Health Sciences (“Next Level”) is an early stage Canadian based company exclusively dedicated to the growing international medical and functional mushroom sector. We are focused on:

- 0.1 creating technology** our competitors can license
- 0.2 developing drugs** that help promote health
- 0.3 providing products** for non-medical consumers



01. Licensable Technology

“Pick and shovel” model where competitors in the mushroom sector can license our technology to enhance the delivery and performance of their drugs and products



02. Pharmaceutical

Focused R&D toward the development of novel indication drugs and medicines that target unmet needs or conditions lacking effective modern treatments



03. Nutraceuticals

Drive near-term revenue through the development and supply of non-regulated functional mushrooms and food products that provide health and wellness support


Global Economic Cost of Mental Disorders



Global Health Medications:
USD \$88B

Sources: National Institutes of Health; Forbes

Expanding Functional Mushroom Opportunity



Targeted Global Functional Food Market:
USD \$34.4B by 2024

Source: Global Functional Mushroom Market to 2024, Research and Markets

“Psychedelics have been a mainstay for a millennia and appreciated in the counter-culture for decades. In 2020, whether consuming, investing, or both, mushrooms are having a moment.”

– Forbes, Jan. 2020

“Demand for functional foods is on the rise as they are believed to impart exceptional health benefits owing to their nutrient content.”

– Grand View Research, April 2020

Milestone Roadmaps



01. Licensable Technology

- Build on existing IP know-how to continue development of proprietary technology for mushroom market
- U.S. Provisional Patent Application filed July 2020 for Methods of Processing Psilocybin Chemical Extracts
- Bring technology developed to date to licensed lab to evaluate and optimize its effect(s) on psychedelic mushrooms
- Sign license agreements with drug & product developers to drive ongoing revenue streams
- Expand stable of licensees over time to increase our attractiveness as an M&A target



02. Pharmaceutical

- Discover R&D gaps and opportunities in mental illness & health sector where mushroom-based formulations could provide unique solutions
- Potential Target Conditions: addiction, depression, OCD, anxiety, TBI (traumatic brain injury), dementia, ADHD
- R&D Approach: Collaborate with leading research lab, CRO (contract research organization) or institution
- Create IP & develop patent portfolio in psychedelic drug space
- Potential Competitive Advantage: Leverage progress on our technology for enhancing drug delivery & performance



03. Nutraceuticals

- Sell our products through online and brick-and-mortar retailers
- Explore two models with speed-to-market being the primary consideration:
 - Model 1: Source leading manufacturers of functional mushroom products in US, Canada and Europe to manufacture, co-pack & distribute products unique to Next Level Brands in those regions
 - Model 2: Leverage existing white label products and their related sales and distribution channels to bring Next Level Brands products to the market

Management Team

David Weinkauf, Founder & Interim CEO, Director

30+ years of strategic business experience, including 2 years in the nutraceutical, pharmaceutical and functional brands market and 4 years in the IP/patent space.

Mark Scott, CTO, Director

Founded food science company focused on cannabis edibles market. Their first product was selected by global food ingredients supplier, Caldic, and is launching in 2020.

Anthony Zelen, Business Development, Director

Serial entrepreneur with over 23 years of experience in finance, investor relations, sales, and corporate development. Involved in over a dozen startups to date.

Malcolm Davidson, CFO, Director

Chartered Professional Accountant with 16+ years of experience in finance, tax, financial accounting, assurance and working with public companies on the TSX and NYSE.

For more information, contact Anthony Zelen at anthony@nextlevelhealthsciences.com

The information provided herein by Next Level Health Sciences (the "Company") is intended solely for discussion purposes and is not intended as, and does not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon in evaluating the merits of investing in any securities. The Company believes the information in this document to be reliable but makes no warranty or representation and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and information provided by unaffiliated third parties and is subject to change without notice. This document may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements about strategic plans, including the Company's ability to implement its business development strategy. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements. All forward-looking statements contained herein are given as of the date hereof and are based upon the opinions and estimates of management and information available to management as at the date hereof. Except as required by law, the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements.